Advertisement
Posters CLINICAL TRIALS & OUTCOME MEASURES| Volume 21, SUPPLEMENT 2, S96, October 2022

163 Long-term safety and efficacy of elexacaftor/tezacaftor/ivacaftor in children 6 years and older with cystic fibrosis and at least one F508del alleles: 96-week interim results from an open-label extension study

DOI:https://doi.org/10.1016/S1569-1993(22)00854-2
163 Long-term safety and efficacy of elexacaftor/tezacaftor/ivacaftor in children 6 years and older with cystic fibrosis and at least one F508del alleles: 96-week interim results from an open-label extension study
Previous Article162 Acceptability and usability of a soft, flexible, wearable device for cough detection in children with cystic fibrosis
Next Article164 Tolerance of ETD001, a long-acting inhaled epithelial sodium channel blocker, in humans
      This paper is only available as a PDF. To read, Please Download here.

      Article info

      Identification

      DOI: https://doi.org/10.1016/S1569-1993(22)00854-2

      Copyright

      © 2022 European Cystic Fibrosis Society. All rights reserved. Published by Elsevier Inc. All rights reserved.

      ScienceDirect

      Access this article on ScienceDirect
      We use cookies to help provide and enhance our service and tailor content. To update your cookie settings, please visit the for this site.
      Copyright © 2023 Elsevier Inc. except certain content provided by third parties. The content on this site is intended for healthcare professionals.


      RELX